This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Wiskott-Aldrich syndrome비스코트-얼드리치증후군 (혈소판감소 및 습진을 동반한 면역결핍)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D82.0 (Wiskott-Aldrich syndrome) | OMIM: 301000 | ORPHA: ORPHA:906 | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsWiskott-Aldrich syndrome, immunodeficiency with thrombocytopenia and eczema, Wiskott-Aldrich syndrome (WAS), Eczema-thrombocytopenia-immunodeficiency syndrome, X-linked thrombocytopenia (XLT, mild phenotype)
C. Adult onsetPossibility of first presenting in adulthood Low (possible in X-linked thrombocytopenia, XLT) — classic WAS presents in infancy; however, in the mild phenotype X-linked thrombocytopenia (XLT), diagnosis may be delayed from late childhood to adulthood, and some cases are first diagnosed by recurrent bleeding or thrombocytopenia.
1. History1937 Wiskott first description (bleeding, eczema, and recurrent infections in three brothers) → 1954 Aldrich (X-linked inheritance confirmed) → 1994 cloning of the WAS gene (Xp11.23) → elucidation of WASP protein function (cytoskeletal regulation) → advances in HSCT and gene therapy.
2. CausesWAS gene (Xp11.23) variant → loss or reduced function of WASP (WAS protein) expression → impaired regulation of the cytoskeleton (actin polymerization) of hematopoietic cells → defective T-cell activation, shortened platelet lifespan, NK/dendritic cell dysfunction.
3. GeneticsX-linked recessive (Xp11.23). More than 500 WAS variants reported. Loss of WASP expression = classic WAS; partially preserved expression or gain-of-function variants = XLT or X-linked neutropenia (XLN).
4. General epidemiologyIncidence about 1/250,000-1/100,000 male infants. Occurs in almost all ethnic groups. A few new diagnoses per year estimated in Korea. Because it is X-linked, it manifests only in males.
5. PathophysiologyWASP deficiency → impaired actin polymerization in T-cell TCR signaling → defective T-cell activation and immune synapse formation. Decreased platelet size and shortened survival. Reduced NK cell and dendritic cell function → predisposition to immunodeficiency, autoimmunity, and malignancy.
6. SymptomsTriad: thrombocytopenia (bleeding tendency), eczema (atopic dermatitis-like), immunodeficiency (recurrent bacterial and viral infections). Increased risk of autoimmune disease (AIHA, ITP, vasculitis) and malignancy (EBV lymphoma).
7. SignsMicrothrombocytopenia, decreased MPV, decreased T cells (over time), decreased serum IgM, elevated IgA, elevated IgE, loss of WASP expression (flow cytometry or immunoblot), confirmation of WAS gene variant.
8. ScreeningEarly genetic testing based on family history (WAS variant), measurement of platelet count and MPV in the neonatal period, serum immunoglobulins. May be detected by TREC screening (when T cells decrease over time).
9. DiagnosisConfirmation of microthrombocytopenia (CBC+MPV), WASP expression (flow cytometry or immunoblot), WAS gene sequencing, immunological evaluation (T-cell function, serum Ig), application of the WAS scoring system.
10. TreatmentHSCT (curative). Gene therapy (lentiviral vector-based, successful phase 1/2 trials). IVIG, prophylactic antibiotics, platelet transfusion (during bleeding), treatment of autoimmunity (steroids, rituximab), live vaccines contraindicated.
11. PrognosisWithout treatment, mean survival 15-20 years. 5-year survival after HSCT 80-90% or higher (HLA-matched donor). Early gene therapy results favorable. Platelet count and immune function may normalize after treatment.
12. PreventionGenetic counseling, identification of X-linked carrier mother, PGT/prenatal diagnosis, early HSCT planning, bleeding prevention (avoiding trauma), infection prevention, live vaccines contraindicated.
13. ReferencesMoratto D et al. Long-term outcome and lineage-specific chimerism in 194 patients with WAS treated by HSCT 1980–2009 … and 9 other papers

1. History

The history of Wiskott-Aldrich syndrome (WAS) goes back to 1937, when the German pediatrician Alfred Wiskott reported a peculiar syndrome in three brothers. Wiskott described that the three boys had a recurrent bleeding tendency (thrombocytopenia), eczematous dermatitis, and recurrent infections, and this was the first clinical description of the syndrome. At that time Wiskott noted that all three affected children were boys, but he could not accurately explain the mode of inheritance.

In 1954, the American Robert A. Aldrich analyzed a Dutch-American family in which the syndrome occurred only in boys over six generations, and confirmed that it follows an X-linked recessive mode of inheritance. As a result, the disease came to be called "Wiskott-Aldrich syndrome (WAS)" after the two physicians. In the 1960s, immunoglobulin abnormalities (decreased IgM, elevated IgA, elevated IgE) were found in WAS patients, and T-cell immune function was also confirmed to decline progressively, making clear that WAS is not a simple platelet disorder but a combined immunodeficiency.

In the 1980s HSCT was attempted as a potentially curative treatment for WAS, and early successful cases began to be reported. In 1994, Derry et al. and Kockaert et al. independently cloned the WAS gene (Xp11.23) and identified the WAS protein (WASP), laying the foundation for studies of molecular mechanisms. WASP was found to be a protein of about 53 kDa expressed specifically in hematopoietic cells and involved in regulating the polymerization of actin, a key component of the cytoskeleton. This discovery presented a new paradigm of WAS as an immunodeficiency caused by deficiency of a cytoskeletal regulatory molecule.

From the late 1990s through the 2000s, the relationship between WAS gene variants and clinical phenotype was elucidated. Variants that completely abolish WASP expression cause classic severe WAS, whereas variants that allow partial WASP expression cause a mild form in which thrombocytopenia is the main phenotype (X-linked thrombocytopenia, XLT). It was also confirmed that gain-of-function variants of the WAS gene cause X-linked neutropenia (XLN). More than 500 WAS variants are registered in the international WAS database. In terms of treatment, clinical trials of WAS gene therapy began in the early 2010s, and the approach of autologous hematopoietic stem cell gene correction using lentiviral vectors has shown positive phase 1/2 clinical results as of 2023-2024.


2. Causes

The cause of WAS is loss or dysfunction of the WAS protein (WASP) expression due to a pathogenic variant of the WAS gene (Xp11.23). The WAS gene is located at Xp11.23 on the short arm of the X chromosome and is a relatively small gene consisting of 12 exons. The mature WASP protein is a protein of about 53 kDa consisting of 502 amino acids, expressed almost exclusively in hematopoietic cells (T cells, B cells, NK cells, platelets, dendritic cells, macrophages).

WASP is a multifunctional protein located at the intersection of intracellular signal transduction and regulation of the actin cytoskeleton. Structurally it consists of the N-terminal WH1 domain (WAS homology domain 1, binding to WASP interacting protein), GBD (GTPase binding domain, Cdc42 binding), PPP (proline-rich domain), and the VCA domain (verprolin homology, cofilin homology, acidic domain, activation of the Arp2/3 complex). At rest, WASP remains inactive through an autoinhibitory intramolecular interaction (autoinhibitory conformation) between the WH1 domain and the VCA domain. When WASP is activated (open form) by TCR or BCR signals, Cdc42 activation through chemokine receptor signals, PI3K signals, SH3 domain binding, and so on, the VCA domain recruits the Arp2/3 complex and promotes branched actin polymerization.

When a loss-of-function variant occurs in the WAS gene, WASP expression is lost or a nonfunctional protein is produced. As a result, cytoskeletal regulatory function is impaired in all WASP-expressing cells, including T cells, B cells, NK cells, and platelets. Various variant types have been reported, including missense, nonsense, splicing, small insertions/deletions, and large deletions. Complete loss of WASP expression causes classic WAS, and when WASP is expressed at a reduced level in some variants (mainly missense in the WH1 domain), a mild phenotype (XLT) appears. Gain-of-function variants (especially in the VCA domain) cause constitutive activation of WASP, resulting in X-linked neutropenia (XLN).


3. Genetics

WAS follows an X-linked recessive mode of inheritance. Therefore it manifests only in boys, and women are carriers who are mostly asymptomatic. If the mother is a carrier, WAS develops in 50% of her sons.

The WAS gene (Gene ID: 7454, Xp11.23) consists of 12 exons and spans about 9 kb of the genome. The WAS protein is composed, from the N-terminus, of WH1 (WASP homology domain 1) - CR (basic region, B domain) - GBD (GTPase binding domain) - PPP (proline-rich region) - VCA (actin binding and Arp2/3 activation domain), in that order. Among these, the WH1 domain is involved in binding to WAS interacting protein (WIP), which contributes to preventing proteolysis and stabilizing WASP.

To date, more than 500 unique variants have been reported in the WAS gene. Variants are distributed across all exons; by type, missense (about 40-50%) is most common, and nonsense, splicing, small insertions/deletions, large deletions, and complex rearrangements are also reported. The list of variants can be found in the international WAS/XLT gene variant database (http://www.shire.com/waspdatabase) and OMIM (301000).

A genotype-phenotype correlation between clinical phenotype and gene variant has been established, but complete prediction is not always possible. In general, variants that completely abolish WASP expression (nonsense, frameshift, splicing variants, large deletions) cause classic severe WAS, and XLT occurs when WASP is expressed at a reduced level in some missense variants of the WH1 domain. An international standardized scoring system for assessing WAS severity (WAS scoring system, 0-5 points) is used in clinical management. For molecular genetic diagnosis, WAS gene sequencing (Sanger or NGS) is performed, and the variant site is evaluated in conjunction with WASP expression (flow cytometry or immunoblot).


4. General epidemiology

The incidence of WAS is estimated at about 1 per 100,000-250,000 male live births. About 10,000-15,000 WAS patients are estimated worldwide, and several hundred new patients are diagnosed each year. As for sex distribution, according to X-linked inheritance it manifests only in boys; female carriers are clinically asymptomatic but show an increased proportion of WASP-negative T cells and B cells on flow cytometry (carrier effect).

WAS is not limited to a specific race or ethnic group and occurs in all races worldwide. Cases have been reported in Europe, North America, Asia, the Middle East, Africa, and elsewhere, and in some populations specific founder variants occur at relatively concentrated frequency. In Korea, it is estimated that several confirmed WAS cases are reported per year, and the number of patients registered under code D82.0 in Health Insurance Review & Assessment Service (HIRA) data is estimated to reach several dozen to date.

In the global ESID registry and PIDTC data, WAS is one of the relatively well-registered diseases among primary immunodeficiencies. The international multicenter study of HSCT in 194 WAS patients during 1980-2009 (Moratto et al., Blood 2011) is the main reference data on WAS treatment outcomes. In Korea, WAS patients are treated at specialized pediatric immunology centers such as Seoul National University Hospital and Samsung Medical Center.


5. Pathophysiology

The pathophysiology of WAS is understood as the loss of regulation of cytoskeletal actin polymerization through WASP, which has wide-ranging effects on the function of hematopoietic cells in general, including T cells, B cells, NK cells, and platelets.

WASP function in T cells and effects of deficiency

When a T cell recognizes an antigen-presenting cell (APC) through the T-cell receptor (TCR)-CD3 complex, TCR signaling activates WASP through Cdc42, PI3K, and others, and the activated WASP recruits the Arp2/3 complex and promotes branched actin polymerization at the site of TCR signaling. This actin polymerization is essential for the formation of the immunological synapse. The immunological synapse is a specialized cell contact site between the T cell and the APC and is critically important for amplifying and sustaining T-cell activation signals. In WASP deficiency, immunological synapse formation is incomplete, so T-cell activation signals are attenuated, and TCR-induced T-cell proliferation, cytokine production (IL-2), and cytotoxic T-cell function are reduced. The decrease in T-cell number over time in WAS patients also reflects a defect in maintaining T-cell homeostasis due to WASP deficiency.

WASP function in B cells and effects of deficiency

In B cells, WASP is involved in actin rearrangement after BCR signaling, cell contact between B cells and T cells and dendritic cells, and differentiation into plasma cells. WASP-deficient B cells show markedly reduced antibody responses to T-cell-independent antigens (Ti-2 antigens, pneumococcal polysaccharides, etc.). This is why WAS patients are vulnerable to encapsulated bacteria (pneumococcus, Haemophilus influenzae, etc.). The decrease in serum IgM also reflects reduced B-cell function.

WASP function in platelets and effects of deficiency

In megakaryocytes, the platelet precursor cells, WASP is involved in regulating the actin cytoskeleton during proplatelet formation and platelet release. In WASP deficiency, microthrombocytopenia, in which platelet size becomes small, and shortened platelet lifespan occur. A mean platelet volume (decreased MPV) much smaller than that of normal platelets is a characteristic finding of WAS. Accelerated abnormal platelet destruction in the spleen also contributes to thrombocytopenia. Microthrombocytopenia (decreased platelet count + decreased MPV) is an important laboratory finding that distinguishes WAS from immune thrombocytopenia (ITP, increased MPV).

Predisposition to autoimmunity and malignancy

Decreased NK cell function, abnormal regulatory T-cell function, and insufficient B-cell negative selection due to WASP deficiency form a predisposition to autoimmune diseases (AIHA, ITP, vasculitis, inflammatory bowel disease, etc.). Reduced EBV immune surveillance increases the risk of EBV-associated B-cell lymphoproliferative disease and lymphoma. The incidence of malignancy in WAS patients is reported to be about 100 times that of the general population.


6. Symptoms

The clinical symptoms of WAS are understood along four axes, centered on the triad of thrombocytopenia, eczema, and immunodeficiency, plus the risk of autoimmune disease and malignancy.

Thrombocytopenia and bleeding symptoms

Thrombocytopenia (generally platelet count 20,000-70,000/μL) and microthrombocytopenia (decreased MPV) appear from early infancy. Clinical symptoms may include petechiae, ecchymosis, bloody stools (bloody diarrhea or hematochezia), epistaxis, and intracranial hemorrhage (rare but fatal). Bloody stool is often the first symptom in young boys and is the trigger for first suspecting WAS.

Eczema

Atopic dermatitis-like eczema appears within several weeks to several months of birth. Pruritus, exudative rash, dry skin, and lichenification appear on the skin of the face, scalp, and flexural areas (inside of the elbows, behind the knees, etc.). It is often more extensive than ordinary atopic dermatitis and responds poorly to treatment. Bleeding due to thrombocytopenia may overlap with the skin lesions.

Infections related to immunodeficiency

Recurrent bacterial infections (otitis media, sinusitis, pneumonia, and sepsis caused by pneumococcus, Haemophilus influenzae, meningococcus, Salmonella, etc.), opportunistic infections (PJP, CMV, HSV, candidiasis), and EBV infection occur. Increased susceptibility to encapsulated bacteria is particularly prominent. There is a risk of disseminated BCG after live BCG vaccination.

Autoimmune diseases and malignancy

Autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP, which must be distinguished from the pre-existing thrombocytopenia), vasculitis, inflammatory bowel disease (IBD)-like symptoms, and autoimmune kidney disease are reported. The risk of EBV-associated B-cell lymphoma (EBV-positive lymphoma), head and neck malignancy, and myeloid malignancy is markedly increased compared with the general population.


7. Signs

Among the characteristic laboratory findings of WAS, microthrombocytopenia is the most important, and loss of WASP expression and abnormal immunoglobulin patterns support the diagnosis.

Hematological findings: a decreased platelet count (generally 20,000-70,000/μL) together with a markedly decreased mean platelet volume (MPV) (normal 7.5-12 fL → 3.5-5.0 fL in WAS) is characteristic. This microthrombocytopenia is the key finding that distinguishes WAS from other thrombocytopenias (ITP: increased MPV; bone marrow dysfunction: normal/decreased MPV, etc.). Small platelet size is confirmed on peripheral blood smear.

Immunological findings: a characteristic pattern of decreased serum IgM, elevated IgA, and elevated IgE appears. Reduced IgG antibody response to polysaccharide antigens (pneumococcus, Haemophilus, etc.). T-cell count is initially normal but decreases over time. Mildly reduced on T-cell function testing (PHA proliferation). WASP expression: loss of WASP protein expression is confirmed in peripheral blood mononuclear cells or T cells by flow cytometry or immunoblot (Western blot) using an anti-WASP antibody. This is an important biochemical test for diagnosing WAS/XLT.

Molecular genetic findings: confirmation of a pathogenic variant on WAS gene sequencing. WAS variant analysis to confirm the mother as a carrier. In female carriers, a mosaic pattern in which WASP-negative and WASP-positive cells coexist (skewed X-inactivation) can be confirmed on flow cytometry.


8. Screening

Screening for WAS consists mainly of family-history-based screening, measurement of platelet count and MPV in male neonates, and WASP expression testing according to clinical suspicion. TREC-based newborn screening has limited detection ability in WAS, where the initial T-cell count is normal, but TREC reduction may appear when the decrease in T-cell count progresses in older children.

Family history-based screening

When a carrier mother of WAS has been identified, the presence of the WAS variant in the fetus is confirmed by prenatal genetic diagnosis during pregnancy (chorionic villus sampling or amniocentesis). A method of selecting unaffected male embryos before implantation through PGT is also possible. In male neonates of WAS families, platelet count and MPV measurement and targeted WAS gene variant analysis are performed immediately after birth.

Screening based on clinical suspicion

WASP expression testing (flow cytometry) is performed in boys with unexplained thrombocytopenia (especially when MPV is low), thrombocytopenia accompanied by eczema, or recurrent infections. If loss or marked reduction of WASP expression is confirmed, the diagnosis is confirmed by WAS gene analysis.


9. Diagnosis

The diagnosis of WAS proceeds in the order of confirming the clinical triad → confirming microthrombocytopenia → WASP expression testing → molecular genetic confirmation.

Step 1: clinical evaluation and hematology tests: confirm the triad (thrombocytopenia, eczema, recurrent infections). Measure platelet count + MPV. Confirm small platelets on peripheral blood smear. A pattern of platelet count 20,000-70,000/μL + MPV < 5 fL suggests WAS.

Step 2: WASP protein expression testing: quantify WASP expression in peripheral blood T cells or monocytes by flow cytometry or immunoblot. Loss of WASP expression suggests classic WAS, and reduced expression (10-60% of normal) suggests XLT.

Step 3: WAS gene sequencing: confirm the pathogenic variant by Sanger analysis of all 12 exons or an NGS panel. The variant type is used to predict WASP expression and clinical severity.

Step 4: immunological evaluation: assess the degree of immunodeficiency by serum immunoglobulins (decreased IgM, elevated IgA/IgE pattern), T-cell subset analysis and function tests, and measurement of specific antibodies after vaccination (pneumococcal polysaccharide IgG, etc.).

Step 5: calculating the WAS clinical score: international standardized WAS score (0-5 points): 1 point (thrombocytopenia + microthrombocytopenia), 2 points (+ eczema), 3 points (+ immunodeficiency), 4 points (+ autoimmunity or malignancy), 5 points (EBV lymphoma). HSCT indication is actively considered at a score of 3 or higher.


10. Treatment

Treatment of WAS is divided into curative treatment through HSCT and supportive treatment. Gene therapy has also recently shown promising results in clinical trials.

Hematopoietic stem cell transplantation (HSCT)

HSCT is the only established curative treatment for WAS. If hematopoietic cells that express WASP normally are reconstituted after transplantation, normalization of platelet count, recovery of immune function, and improvement of eczema are expected. Outcomes of transplantation from an HLA-matched sibling donor are the best (5-year survival 90% or higher), and transplantation from an unrelated HLA-matched donor (5-year survival 70-80%) is also favorable. Recently, outcomes of haploidentical transplantation have improved with advances in TCRαβ/CD19-depleted haploidentical transplantation techniques. There are reports that transplantation before age 5 has a better prognosis, and HSCT is strongly recommended at a WAS score of 3 or higher.

Gene therapy

Autologous CD34+ hematopoietic stem cell gene correction using lentiviral vectors has been performed in phase 1/2 clinical trials. Studies by the groups of Aiuti et al. (Milan), Hacein-Bey-Abina et al. (Paris), and Braun et al. (Frankfurt) reported recovery of platelet count, normalization of immune function, and resolution of autoimmunity, and long-term survival was achieved without GVHD. Autologous gene therapy has the advantages of no GVHD risk and solving the problem of donor unavailability, but additional data on the risk of insertional mutagenesis and long-term efficacy continue to accumulate.

Supportive care

IVIG (regular administration, at 4-week intervals), prophylactic antibiotics (TMP-SMX, penicillin), prophylactic antifungals, bleeding prevention (avoiding contact sports, minimizing the risk of intracranial hemorrhage), platelet transfusion (for severe bleeding or before surgery, platelets < 10,000/μL), skin care (topical steroids, antihistamines), treatment of autoimmunity (steroids, rituximab, cyclosporine, etc.), live vaccines absolutely contraindicated. Use irradiated and CMV-negative blood products for transfusion.

Splenectomy

Splenectomy can temporarily improve platelet count by reducing platelet destruction in the spleen, but in a patient not prepared for HSCT, loss of splenic immune function may increase vulnerability to infection by encapsulated bacteria, so the decision is made carefully.


11. Prognosis

The prognosis of WAS has changed greatly before and after the era of treatment. In the past, the mean survival of untreated WAS patients was about 15-20 years, and the main causes of death were bleeding (especially intracranial hemorrhage), infection, autoimmune disease, and malignancy. Prognosis has now improved greatly with advances in HSCT and gene therapy.

Prognosis after HSCT: in an international multicenter study (Moratto et al., Blood 2011; 1980-2009, 194 patients), overall 5-year survival after HSCT was reported as 83%. 5-year survival was reported as about 90% with HLA-matched sibling donor transplantation, about 75-85% with unrelated HLA-matched donor transplantation, and about 60% with haploidentical transplantation. Outcomes were better when transplantation was performed before age 5. After HSCT, normalization of platelet count, recovery of immune function, and improvement of eczema are expected. After successful transplantation, the risk of autoimmune disease and malignancy also decreases.

Gene therapy results: in clinical trials of lentiviral vector-based gene therapy conducted since the early 2010s, recovery of platelet count, normalization of immune function, and resolution of autoimmunity have been reported in many patients, and safety has also been confirmed in long-term follow-up. Successful results have been reported in more than 50 patients to date. Gene therapy can be an important alternative when no HLA-matched donor is available. Long-term management: even after successful HSCT, chronic GVHD, PTLD, malignancy risk follow-up, endocrine function, and growth and development are regularly evaluated.


12. Prevention

Prevention of WAS consists of reducing genetic risk, preventing complications, and early treatment.

Primary prevention: genetic counseling and reproductive choices

Genetic counseling is provided to carrier mothers of WAS (50% risk of affected sons), and options of PGT (confirmation of sex and WAS variant before implantation) or prenatal genetic diagnosis (CVS or amniocentesis) are explained for the next pregnancy. Carrier status is also tested in maternal family members (maternal aunts, maternal grandmother, etc.) to identify at-risk families early.

Secondary prevention: early diagnosis and prevention of bleeding and infection

Early diagnosis by platelet count and MPV measurement and WAS gene analysis immediately after birth in male neonates of WAS families. After diagnosis, activity restriction to prevent intracranial hemorrhage and avoidance of contact sports until HSCT is planned. Infection prevention (TMP-SMX, IVIG, live vaccines contraindicated). Use irradiated blood products for transfusion.

Tertiary prevention: minimizing long-term complications after HSCT

After HSCT, chronic GVHD, malignancy, autoimmune recurrence, endocrine function, and growth and development are regularly followed up. Psychological and social support and guidance to WAS patient organizations (WAS Foundation, etc.) are provided to the family.


13. References

  1. Moratto D, Gaspar HB, Forino C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood. 2011;118(6):1675–1684. DOI: 10.1182/blood-2010-11-319376. PMID: 21659547.

  2. Derry JMJ, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78(4):635–644. DOI: 10.1016/0092-8674(94)90528-2. PMID: 8069912.

  3. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nature Reviews Immunology. 2010;10(3):182–192. DOI: 10.1038/nri2724. PMID: 20182458.

  4. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151. DOI: 10.1126/science.1233151. PMID: 23845947.

  5. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. Science Translational Medicine. 2014;6(227):227ra33. DOI: 10.1126/scitranslmed.3007280. PMID: 24622513.

  6. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456–464. DOI: 10.1182/blood-2003-05-1556. PMID: 14504097.

  7. Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology. 2006;117(4):725–738. DOI: 10.1016/j.jaci.2006.02.005. PMID: 16585079.

  8. Worth AJ, Thrasher AJ. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Review of Clinical Immunology. 2015;11(9):1015–1032. DOI: 10.1586/1744666X.2015.1062365. PMID: 26192822.

  9. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.

  10. Bousfiha A, Jeddane L, Picard C, et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. Journal of Clinical Immunology. 2020;40(1):66–81. DOI: 10.1007/s10875-019-00722-4. PMID: 32048120.